Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
28 Junho 2023 - 8:00AM
Business Wire
- The academic proof-of-concept open-label study evaluated the
biological activity, cytokine and chemokine blood biomarkers,
safety, and preliminary efficacy of low-dose interleukin-2 (ld
IL-2) in 8 patients with mild-to-moderate AD. The study was
conducted by Dr. Appel and Dr. Faridar at the Houston Methodist
Hospital.
- Coya’s investigational low-dose interleukin-2 (ld IL-2) for
subcutaneous administration has been designed to enhance in vivo
the anti-inflammatory function of regulatory T cells (Tregs).
- Treg dysfunction has been associated with increased
neuroinflammation, which is observed in AD and other
neurodegenerative diseases, and may contribute to disease severity
and progression.
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
multiple therapeutic platforms intended to enhance Treg function,
today announced the presentation of results from an academic
clinical study in patients with Alzheimer’s Disease (AD) with
subcutaneous ld IL-2 at the 2023 Alzheimer’s Association
International Conference (AAIC) to be held in Amsterdam,
Netherlands, from July 16-20, 2023.
The proof-of-concept open-label clinical study is the
first-of-its-kind evaluating subcutaneous ld IL-2 immunotherapy for
the treatment of AD. Patients in the study received investigational
ld IL-2 treatment for 4 consecutive months and were evaluated for
safety and tolerability, Treg function, blood biomarkers of
inflammation, and clinical functioning as measured by the Clinical
Dementia Rating (CDR), the Alzheimer’s Disease Assessment
Scale–Cognitive Subscale (ADAS-Cog), and the Mini-Mental State
Examination (MMSE).
Alzheimer’s disease is a progressive neurological condition
usually seen in people over the age of 65 in which the death of
brain cells causes memory loss and cognitive decline. It is the
most common type of dementia, accounting for around 60–80% of cases
of dementia in the United States. Alzheimer’s disease affects
around 5 million people in the US with estimates suggesting that
this number will nearly triple by 2060.
The study was conducted by Stanley Appel, M.D. and Alireza
Faridar, M.D. at the Houston Methodist Research Institute (Houston,
Texas). Dr. Appel is chair of Coya’s Scientific Advisory Board and
is former chair of the Stanley H. Appel Department of Neurology. He
is the director of the Ann Kimball & John W. Johnson Center for
Cellular Therapeutics, Professor of Neurology at Weill Cornell
Medical College, and the Peggy and Gary Edwards Distinguished Chair
for the Treatment and Research of ALS at the Houston Methodist
Research Institute.
Presentation details:
- Title: A Phase 1 Clinical Trial of IL-2 in Patients with
Alzheimer’s Disease: A Regulatory T Cell Expansion Strategy
Targeting Inflammation
- Date: July 16, 2023
- Conference: 2023 Alzheimer’s Association International
Conference (aaic.alz.org)
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system. Coya’s investigational
product candidate pipeline leverages multiple therapeutic
modalities aimed at restoring the anti-inflammatory and
immunomodulatory functions of Tregs. Coya’s lead product
candidates, COYA 301 and COYA 302, are biologic therapies intended
to enhance Treg function and expand Treg numbers. COYA 301 is a
cytokine biologic for subcutaneous administration intended to
enhance Treg function and expand Treg numbers in vivo, and COYA 302
is a biologic combination for subcutaneous and/or intravenous
administration intended to enhance Treg function while depleting T
effector function and activated macrophages. These two mechanisms
may be additive or synergistic in suppressing inflammation. For
more information about Coya, please visit
www.coyatherapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements.
Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but
not limited to, those related to risks associated with the impact
of COVID-19; the success, cost and timing of our product candidate
development activities and ongoing and planned clinical trials; our
plans to develop and commercialize targeted therapeutics; the
progress of patient enrollment and dosing in our preclinical or
clinical trials; the ability of our product candidates to achieve
applicable endpoints in the clinical trials; the safety profile of
our product candidates; the potential for data from our clinical
trials to support a marketing application, as well as the timing of
these events; our ability to obtain funding for our operations;
development and commercialization of our product candidates; the
timing of and our ability to obtain and maintain regulatory
approvals; the rate and degree of market acceptance and clinical
utility of our product candidates; the size and growth potential of
the markets for our product candidates, and our ability to serve
those markets; our commercialization, marketing and manufacturing
capabilities and strategy; future agreements with third parties in
connection with the commercialization of our product candidates;
our expectations regarding our ability to obtain and maintain
intellectual property protection; our dependence on third party
manufacturers; the success of competing therapies or products that
are or may become available; our ability to attract and retain key
scientific or management personnel; our ability to identify
additional product candidates with significant commercial potential
consistent with our commercial objectives; and our estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230628076008/en/
Investor Contact David Snyder
david@coyatherapeutics.com
Hayden IR James Carbonara (646)-755-7412 James@haydenir.com
Media Contact Ari Zoldan Quantum Corp.
ari@quantum-corp.com
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024